Hormonal
Deletion or inhibition of MKK6 in white adipose tissue increases energy expenditure and protects against diet-induced obesity and diabetes by enhancing thyroid hormone (T3)-mediated browning of white fat.
This research suggests that blocking MKK6 in fat tissue could help treat obesity by making fat burn more energy, similar to brown fat. While not a current human treatment, it highlights thyroid hormone sensitivity and fat metabolism as key targets for future obesity drugs.
Deletion of Mkk6 increases T3-stimulated UCP1 expression in adipocytes, thereby increasing their thermogenic capacity... These results indicate that MKK6 is a central regulator of WAT browning and is a possible target for obesity treatment.
Why this rating
Strong evidence from multiple mouse models (global knockout, conditional knockout, shRNA knockdown) and human tissue analysis, though human clinical trials are not yet reported.
Source
MKK6 controls T3-mediated browning of white adipose tissue
Nuria Matesanz et al. · Nature Communications · 2017
DOI 10.1038/s41467-017-00948-z
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →